Division of Endocrinology, Department of Medicine, Mayo Clinic in Florida, Jacksonville, Florida
Division of Endocrinology, Department of Medicine, Mayo Clinic in Florida, Jacksonville, Florida.
J Nucl Med. 2021 Jul;62(Suppl 2):13S-19S. doi: 10.2967/jnumed.120.246025.
Thyroid nodules (TN) are prevalent in the general population and represent a common complaint in clinical practice. Most are asymptomatic and are associated with a 7%-15% risk of malignancy (). PubMed and Medline were searched for articles with a focus on the epidemiology, diagnosis, and management of TN over the past 5 y. The increase in frequency of imaging has led to a rise in the incidence of incidentally diagnosed TN. The initial evaluation of a TN includes assessing thyroid function, clinical risk factors, and neck imaging. Ultrasound remains the gold standard for assessing TN morphology, and biopsy is the standard method for determining whether a TN is benign. Recently published risk stratification systems using morphologic characteristics on ultrasonography have been effective in reducing the number of unnecessary biopsies. Advances in molecular testing have reduced the number of surgical procedures performed for diagnostic purposes on asymptomatic TN with indeterminate cytology. Scintigraphy is the first-line study for assessing a hyperfunctioning nodule. Many TN can be followed clinically or with serial ultrasound after the initial diagnosis. Surgical intervention is warranted when local symptoms are present, in patients with clinical risk factors, as well as in most situations with malignant cytology. Active surveillance is an option in cases of micropapillary thyroid cancer. Emerging nonsurgical approaches for treating TN include ethanol ablation for TN; sclerotherapy for thyroid cysts; and thermal techniques, such as radiofrequency ablation, laser ablation, microwaves, and high-intensity focused ultrasound. Most TN are benign and can be safely monitored. The indications for biopsy and frequency of imaging should be tailored on the basis of risk stratification. Treatment options should be individualized for each patient's particular situation. Active surveillance should be considered in certain cases of papillary microcarcinoma.
甲状腺结节(TN)在普通人群中很常见,是临床实践中的常见病症。大多数甲状腺结节没有症状,恶性肿瘤的风险为 7%-15%()。本文对过去 5 年中关于甲状腺结节的流行病学、诊断和管理的文献进行了检索,重点关注这些方面。由于影像学检查的频率增加,偶然诊断出的甲状腺结节发病率也有所上升。甲状腺结节的初步评估包括评估甲状腺功能、临床危险因素和颈部影像学检查。超声检查仍然是评估甲状腺结节形态的金标准,而活检是确定甲状腺结节是否为良性的标准方法。最近发表的基于超声形态特征的风险分层系统在减少不必要的活检数量方面非常有效。分子检测技术的进步减少了对无症状、细胞学不确定的甲状腺结节进行诊断性手术的数量。核素扫描是评估功能亢进性结节的首选研究方法。许多甲状腺结节在初始诊断后,可以通过临床或连续超声进行随访。当出现局部症状、有临床危险因素时,以及在大多数恶性细胞学情况下,需要进行手术干预。对于微小乳头状甲状腺癌,可以选择主动监测。治疗甲状腺结节的新非手术方法包括甲状腺结节乙醇消融术;甲状腺囊肿硬化疗法;以及热技术,如射频消融术、激光消融术、微波和高强度聚焦超声。大多数甲状腺结节是良性的,可以安全监测。活检的适应证和影像学检查的频率应根据风险分层进行调整。应根据每个患者的具体情况制定个体化的治疗方案。在某些微小乳头状癌的情况下,可以考虑主动监测。
J Nucl Med. 2021-7
Cochrane Database Syst Rev. 2014-6-18
Annu Rev Med. 2022-1-27
Endocr Metab Immune Disord Drug Targets. 2024
J Clin Endocrinol Metab. 2020-9-1
Endocrinol Diabetes Nutr (Engl Ed). 2021-12
Medicine (Baltimore). 2025-8-22
Cell Death Discov. 2024-8-26
Endocr Metab Immune Disord Drug Targets. 2024
Sisli Etfal Hastan Tip Bul. 2023-12-29
Int J Gen Med. 2023-12-22